U.S. Markets closed
  • S&P 500

    3,635.41
    +57.82 (+1.62%)
     
  • Dow 30

    30,046.24
    +454.97 (+1.54%)
     
  • Nasdaq

    12,036.79
    +156.15 (+1.31%)
     
  • Russell 2000

    1,853.53
    +35.23 (+1.94%)
     
  • Crude Oil

    44.78
    +1.72 (+3.99%)
     
  • Gold

    1,804.20
    -33.60 (-1.83%)
     
  • Silver

    23.25
    -0.38 (-1.62%)
     
  • EUR/USD

    1.1896
    +0.0051 (+0.4283%)
     
  • 10-Yr Bond

    0.8820
    +0.0250 (+2.92%)
     
  • Vix

    21.64
    -1.02 (-4.50%)
     
  • GBP/USD

    1.3363
    +0.0041 (+0.3087%)
     
  • USD/JPY

    104.4440
    -0.0440 (-0.0421%)
     
  • BTC-USD

    18,949.79
    +497.83 (+2.70%)
     
  • CMC Crypto 200

    376.18
    +6.43 (+1.74%)
     
  • FTSE 100

    6,432.17
    +98.33 (+1.55%)
     
  • Nikkei 225

    26,165.59
    +638.22 (+2.50%)
     

Recap: Boston Scientific Q2 Earnings

Benzinga Insights
·1 min read

Shares of Boston Scientific (NYSE:BSX) moved higher by 0.6% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were down 79.49% year over year to $0.08, which beat the estimate of ($0.03).

Revenue of $2,003,000,000 declined by 23.87% year over year, which beat the estimate of $1,710,000,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Jul 29, 2020

View more earnings on BSX

Time: 08:00 AM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/514/35543

Price Action

52-week high: $46.62

52-week low: $24.10

Price action over last quarter: Up 2.19%

Company Profile

Boston Scientific produces less-invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract tests, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.